Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage II Pleural Mesothelioma Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
GC1008
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
Interventions
L-alanosine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • La Verne, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced May 21, 2026, 10:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
trabectedin
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Mesothelioma
Interventions
pemetrexed disodium, gemcitabine hydrochloride, carboplatin
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
115
States / cities
Norwich, Connecticut • Lewes, Delaware • Newark, Delaware + 79 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced May 21, 2026, 10:15 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Mesothelioma
Interventions
Velcade (bortezomib) plus Eloxatin (oxaliplatin)
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2011 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pleural Neoplasms
Interventions
pemetrexed, cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2009 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced May 21, 2026, 10:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
Interventions
laboratory biomarker analysis, pazopanib hydrochloride
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Mesothelioma, Pleural Mesothelioma
Interventions
Durvalumab
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced May 21, 2026, 10:15 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Mesothelioma
Interventions
Pleurectomy/Decortication, pemetrexed and cisplatin or carboplatin, Intensity Modulated Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
12
States / cities
Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma
Interventions
Nintedanib
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced May 21, 2026, 10:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
Interventions
Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
231
States / cities
Rogers, Arkansas • Antioch, California • Burbank, California + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
Interventions
oncolytic measles virus encoding thyroidal sodium iodide symporter, laboratory biomarker analysis, single photon emission computed tomography, computed tomography
Biological · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Mesothelioma
Interventions
Pemetrexed, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
10
States / cities
Aurora, Colorado • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma
Interventions
lung tumor associated antigen, DetoxPC, chemotherapy, cyclophosphamide
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
cediranib maleate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Mesothelioma
Interventions
Carboplatin, Bevacizumab and Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Pleural Mesothelioma
Interventions
Doxorubicin, Cisplatin, Pemetrexed, Radiotherapy
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
capecitabine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced May 21, 2026, 10:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Mesothelioma, Homologous Recombination Deficiency
Interventions
Olaparib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Pleural Mesothelioma, Solid Tumors
Interventions
pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin, pemetrexed, cisplatin and CBP501, dose finding
Drug
Lead sponsor
CanBas Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced May 21, 2026, 10:15 PM EDT